Pharmacy | October 20, 2020

GSK Consumer Healthcare Requests Halt of Excedrin® Sale & Teva Pharmaceuticals Releases Generic Truvada

Learn how these two drug updates could affect the workers' compensation and auto casualty industries. 

Excedrin® Lots

On October 7, 2020, GSK Consumer Healthcare requested retailers halt sales of certain Excedrin® lots. According to GSK, the request was made “due to the possibility of holes in the bottles that have been supplied by the bottle manufacturer.”

The following products (in 50, 80, 100, 125, 200, 250 and 300 count) are affected:

  • Excedrin® Migraine Caplets/Geltabs
  • Excedrin® Extra Strength Caplets
  • Excedrin® PM Headache Caplets
  • Excedrin® Tension Headache Caplets

Products not affected by the request are:

  • Excedrin® Extra Strength Caplets (24-count bottle)
  • Excedrin® Migraine Caplets/Geltabs (24-count bottle)

As most of these products are sold as over-the-counter medications, Mitchell Pharmacy Solutions does not expect a large impact to workers’ compensation or auto casualty programs. We will continue to monitor the overall impact of the halt of sale request.

Generic Truvada®

Additionally, on October 7, 2020, Teva Pharmaceuticals, the makers of Truvada®, announced the first generic for Truvada®. Truvada®, a combination of emtricitabine and tenofovir, is an antiretroviral drug that is used to manage HIV1 infections and for HIV1 pre-exposure prophylaxis (PrEP). Truvada® can also be used along with other anti-HIV drugs for post-exposure prophylaxis (PEP) shortly after possible exposure to an HIV infection.

In workers’ compensation, the Official Disability Guidelines (ODG) recommends the use of Truvada® along with Isentress® (raltegravir) for use in PEP cases. Many state workers’ compensation formularies also include conditional coverage of specialty drugs for PEP. Workers’ compensation cases typically involve inadvertent workplace exposures such as needle stick or bodily fluid exposure in healthcare, laboratory, public sanitation and emergency response settings.  

Teva Pharmaceuticals has an exclusive right to market the generic product for six months until the brand patent expires, wherein competitors may launch their own generic products. We expect this to create a modest reduction in cost for those first six months and subsequently a larger reduction when additional products enter the market.

Mitchell Pharmacy Solutions will continue to monitor this situation and work with our clients to adjust formularies as necessary.

For any questions on this alert, please contact your Client Services Manager.

The Latest in

Filter By

Related News

{{ArticleCategory(article)}} MPower



{{article.ShortDescription | text}}

More News

Terms of Use | Privacy Practices | Copyright & Usage | [+} Report a Problem
© 2021 Mitchell International, Inc. All Rights Reserved.
By accessing, each user agrees that they have read and agreed to be bound by the
Terms and Conditions governing and Privacy Policies governing